Hyperphosphatemia is present in patients with end-stage renal disease and is increasingly important as a clinical entity. Several studies have shown that calcium acetate is more cost-effective than sevelamer as a phosphate binder. Calcium acetate can be used effectively with doses of elemental calcium that meet the K/DOQI guidelines.
The CARE Study and Cardiovascular Calcification
Controversies in the Management of Hyperphosphatemia in Patients With End-Stage Renal Disease